RE: PK study delay18 Nov 2021 08:23
This is what the company said when it announced the Avion deal:
'A new optimised international Phase III trial in lupus patients (which is expected to include patients in the US, Europe and elsewhere), is targeted to commence in 2020, following agreement of the trial design between Avion, ImmuPharma and the US Food & Drug Administration'
So assuming the PK trial is successful the start of the phase 3 trial will be 2 years late